Trial Profile
Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Natural killer cell therapy Shenzhen Hank Bioengineering Institute (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Sep 2019 Status changed from recruiting to completed.
- 04 Jul 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified July 2016).
- 27 Jul 2016 New trial record